Royalty Report: Drugs, Antibody, Cancer – Collection: 144995

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Drugs
  • Antibody
  • Cancer
  • Disease
  • Therapeutic
  • Diagnostic
  • Immune
  • Drug Discovery
  • Biotechnology
  • DNA
  • Delivery
  • Technical Know How
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 144995

License Grant
Licensor grants an exclusive license in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Know-How, to make, have made, use and sell Products in the Field.  During the research term, the Licensor shall not perform any research or development work in the field with any other party.
License Property
L6 Antibodies shall mean those certain Program Antibodies that are murine or chimeric antibodies and are specifically reactive immunologically with the L6 antigen, such L6 antigen having characteristics substantially  described, as amended, supplemented or modified from time to time.
Field of Use
The Field shall mean the in vivo diagnosis or treatment of solid tumors in humans through the use of one or more antibodies.

The Diagnostic Product shall mean a diagnostic product, containing one or more Program Antibodies, for use in the in vivo detection of solid tumors in humans.

The Therapeutic Product shall mean the final dosage formulation of a product incorporating pharmaceutical compositions containing a Program Antibody for use in the treatment of solid tumors in humans, regardless of the route of administration. Each different chemical formulation of a Therapeutic Product containing the same one or more Program Antibodies but no additional antibodies, except different formulations for use in the treatment of the same indication in the Field by different routes of administration, shall constitute a different Therapeutic Product.

IPSCIO Record ID: 6797

License Grant
Licensor hereby grants to Licensee a right and license or, in the case of Patents licensed to Licensor under the Licensor In-Licenses, a sublicense, under the Licensed Technology, to make, have made, use, offer to sell, sell and have sold Products except as set forth in this agreement in the relevant Field, and in the Territory.
License Property
Table 1 BR96sFv-PE40 Program

The following patents and patent applications, together with the know-how related thereto, constitute the BR96 sFV-PE40 Program

Patent
  
Description
License Type

Number
Number

57,444
5,491,088
  
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive

459,354

  
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive

Table 2 BR96/Drug Conjugate Program

Application
Patent
  
Description
License Type

Number
Number

353,729
5,122,368
  
Linker chemistry having an acylhydrazone linkage through C13 keto group of anthracycline to nonimmunoglobulin ligand. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers

96,628

  
Acylhydrazone linkage through C13 keto group of anthracycline to immunoglobulin. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers

824,951
5,622,929
  
Anthrecycline ligand conjugates where linkage is an acylhydrazone through C13 keto position of anthracycline. Linker also contains succinimido moiety. Chemistry is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

08/468,162
5,606,017
  
Anthracycline intermediate having acylhydrazone linkage through C13 keto position of anthracycline and a Michael Addition Receptor. Intermediate in conjugation used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

08/469,840

  
Process for conjugation using intermediate above with reduced immunoglobulin to increase total drug to antibody yield. Process is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers

62,366

  
Enzyme cleavable peptide linker for making cytotoxic drug ligand conjugates. Linkers are used to make second generation BR96-Dox.
Partially-Exclusive for Linkers

57,444
5,491,088
  
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive

77,253

  
Immunoconjugates of murine monoclonal antibody BR96, chimeric BR96 and other recombinant antigen binding fragments. Includes single chain and bispecific recombinant constructs.
Exclusive

333,840

  
Methods of treating human carcinoma by administering murine BR96, chimeric BR96 or any recombinant antigen binding construct either by itself or conjugates with various agents. Also includes diagnostic kits.
Exclusive

459,354

  
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive

08/285,936

  
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive

08/487,860

  
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive

60/030/367

  
Branched peptide linker for linking thiol group on targeting ligand to two or more drug moieties.
Partially-Exclusive for Linkers

5,204,244
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

5,202,238
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

5,482,856
  
Production of chimeric antibodies by homologous recombination.
Non-Exclusive

Table 3 G28-5 SfV/Immunotixin Program

The patents and patent applications (the “Washington Patents”), together with the know-how related thereto, sublicensed under the Washington Agreement constitute the G28-5 sFv/Immunotoxin Program. [Exclusive]

Table 4 BD1 Program

The following patents and patent applications, together with the know-how related thereto, constitute the BD1 Program

Application
Patent
Description
License Type

Number
Number

08/245,754
5,541,110
Isolated oligonucleotide sequence encoding Bryodin 1, recombinant vectors and plasmids, and transfected host cells.
Exclusive

08/597,731

Methods for the recombinant production of Bryodin 1 and Bryodin 1-ligand fusion proteins.
Exclusive

08/324,301
5,597,569
Ribosome-inactivating protein Bryodin 2 in an isolated form, linked to a ligand as a conjugate or a fusion protein, pharmaceutical compositions, nucleotide sequence, transfected host cells and recombinant production.
Exclusive

Table 5 ADEPT Program

The following patents and patent applications, together with the know-how related thereto, constitute the ADEPT Program

Application

Number
Patent
Description
License Type

(filed 5/7/96)
Number

Recombinant L49sFv-¨ lactamase fusion proteins which recognize p97 melanoma antigen and activate-cephalosporin derivatized prodrug molecules.
Exclusive

211,301
4,975,278
Methods for delivering cytotoxic agents to tumor cells by administering an effective amount of at least one antibody-enzyme conjugate, wherein the antibody is specific for a tumor associated antigen and the enzyme converts at least one weakly cytotoxic prodrug to its corresponding cytotoxic parental form; and the administration of an effective amount of the prodrug.
Non-Exclusive

Table 6 Residual Program

The following patents and patent applications, together with the know-how related thereto, constitute the Residual Program

Application
Patent
Description
License Type

Number
Number

684,759
4,935,495
Monoclonal antibodies, Fab, F(ab1)2 or Fv fragments thereof which compete for binding with L6 to its antigen.
Partially-Exclusive for Cancer

776,321
4,906,562
Methods for detecting malignancy using L6 or other monoclonal antibodies or fragments thereof which compete with L6 for binding to its antigen.
Exclusive

523,309
5,091,177
Method for reducing population of tumor cells using L6 or monoclonal antibodies which compete for binding with L6 to its antigen.
Exclusive

443,696
5,242,824
Monoclonal antibody BR64 and antigen binding fragments thereof.
Exclusive

08/726,528

Monoclonal antibodies and recombinant antigen binding molecules which recognize the G733-1 but not G733-2 antigen. Specifically BR110.
Partially-Exclusive for Cancer

527,227
5,165,922
Method of treating breast carcinoma in an unresponsive patient by first administering monoclonal antibody L6 followed by administration of a chemotherapeutic agent.
Exclusive

5,663,158
Method for treating vascular leak syndrome.
Non-Exclusive

The Residual Program also includes antibodies L6, L49, BR64, BR110, OV578.1 and OV569.1 [Exclusive]

Field of Use
Field shall be the treatment and diagnosis of cancer in humans.

The Field with respect to Licensed Technology for which Licensee is granted a right and license that is partially exclusive shall be

(i) if this Agreement indicates that such license is partially exclusive for linkers, all monoclonal antibody targeting applications; or (ii) if the agreement indicates that such license is partially exclusive for cancer, the treatment and diagnosis of cancer in humans. The Field with respect to Licensed Technology for which Licensee is granted a right and license that is non-exclusive shall be the treatment and diagnosis of cancer in humans. Notwithstanding the foregoing, the Field with respect to the G28-5 Licensed Technology shall be for the use of the antibody G28-5 fused with a toxin for the treatment of cancer in humans.

IPSCIO Record ID: 289177

License Grant
With this agreement, Licensee wishes Licensor to apply its technology and know-how to genetically engineer a Single-Chain Antibody.

The Licensor of Scotland agrees to grant the German Licensee under the patent rights a non-exclusive world-wide licence to the extent necessary to commercialise the Deimmunised antibody and/or the deliverables in the field.

Licensor grants for each specific Deimmunised antibody a non-exclusive licence under the patent rights to the extent necessary for worldwide commercialisation of the Deimmunised antibody derived from the specific Single-Chain Antibody sequence.

License Property
Licensor has certain proprietary technology, materials and know-how in genetic engineering of biological materials, including single-chain antibodies, relating to removal of potentially immunogenic sequences, from the variable regions of antibodies, or Delmmunisation to produce an antibody for therapeutic and/or in vivo diagnostic purposes.

Licensee is the owner of a cDNA which encodes a Single-Chain Antibody which binds to a specific antigen.

Licensor patent rights shall mean all patent applications and granted patents relevant to Deimmunization Technology.

Deimmunised antibody shall mean all genetically engineered variant(s) of the single-chain antibody  arising from the research.

Deimmunization technology shall mean the technical process applied by Licensor to generate Deimmunised antibody as outlined in the research program.

DeImmunisation increases the clinical potential of antibody and protein therapeutics by eliminating/reducing the T-cell response caused when the therapeutic molecule is recognised as foreign by the patient's immune system. The technology is based on ‘peptide threading' and works by identifying potential T-cell epitopes on the therapeutic antibody or protein. T-cell epitopes are sites on the therapeutic molecule which can bind to MHC class II, triggering a T-cell mediated immune response. Once this potentially immunogenic region of the antibody is identified, it is removed from the molecule by single amino acid substitutions, thus eliminating/reducing the therapeutic antibody or protein's immunogenicity and increasing its safety. This can be done without compromise to efficacy.

Field of Use
The field shall mean the field of human therapy and human in vivo and in vitro diagnostics limited to the Single-Chain Antibody.

IPSCIO Record ID: 233496

License Grant
Pursuant to this agreement, the Licensee has the right to grant sub-licenses to Licensees product.  The Licensee may grant a Sublicense with respect to any Licensee Product for use in the Therapeutic Field, and, the Diagnostic Field.

During the Research term of this agreement, Licensee shall not make any other grant to the related antigens.

License Property
Licensee Product shall mean, with respect to any Licensee Licensed Antigen, any product comprising an Antibody which binds to such Licensee Licensed Antigen, or Genetic Material that encodes such an Antibody wherein, in respect of each Licensee Product, said Genetic Material does not encode multiple antibodies.

Antigens shall mean, collectively, the Research Antigens, Eligible Antigens, Optioned Antigens and Licensed Antigens, and Antigen shall mean any one of the Antigens.

Research Antigens shall mean, collectively, the antigens which are selected by the Collaboration, Licensor or Licensee for use in the Research Program, for which Licensor and Licensee have the right to grant the other party the commercial license, and which are not Optioned Antigens or Licensed Antigens, and Research Antigen shall mean any one of the Research Antigens.

Field of Use
The Commercial Field shall mean, collectively, the Therapeutic Field and the Diagnostic Field.

The Diagnostic Field shall mean the use of Products for the following human medical purposes the detection, diagnosis and monitoring of any disease, predisposition, state or condition in humans or the selection of a particular patient(s) to receive a particular therapeutic treatment(s).

The Therapeutic Field shall mean the use of Products for the following human medical purposes the prevention or treatment of any disease, state or condition in humans.

The goal of the five-year alliance is to develop antibody therapeutics against promising antibody drug targets in the human genome. The candidates are intended to treat a broad range of diseases, including metabolic diseases, cancer, inflammation, and autoimmune disorders.

IPSCIO Record ID: 203353

License Grant
This agreement is for Collaborative Research. The goal of the Program is to humanize and optimize Candidate Molecules.  The plan includes antibody cloning, assay development and validation, design and synthesis of Humanization/Optimization Libraries, Screening, Characterization, Affinity Maturation, Iterative Affinity Maturation and Deliverables.

Licensor shall optimize and humanize the Candidate Molecules as set forth in the Research Plan. Licensor shall use its commercially reasonable efforts to perform its obligations under the Program in accordance with the Research Plan. Licensor shall provide the personnel, materials, equipment and other resources required to conduct its obligations under the Program. Licensor shall perform its obligations under the Program in accordance with high scientific and professional standards, and in compliance in all material respects with the requirements of applicable laws and regulations.

Licensee shall use its best efforts to actively research, develop and obtain regulatory approvals to market in major markets throughout the world at least one Product.

License Property
Product shall mean any product for use in the Field, which is a composition that incorporates one or more Program Antibodies or is derived from one or more Program Antibodies.

The Candidate Molecules shall mean, collectively, monoclonal antibody (mAb) HUIV26 and mAb HUI77 as provided by Licensee to Licensor.

Materials shall mean the Candidate Molecules, DNA sequence information and the cDNA to encode Candidate Molecules and the hybridoma cell lines expressing the Candidate Molecules.

Program Antibody shall mean the optimized and humanized compositions of matter developed under the Program, and the cDNA encoding such compositions of matter, delivered to Licensee.

Licensor utilizes its technology to humanize a murine monoclonal antibody, which is now referred to as D93, and another of our anti-angiogenic monoclonal antibodies.

Field of Use
The Field shall mean human and veterinary therapeutic and diagnostic applications.

D93 is humanized, anti-angiogenic monoclonal antibody, in patients with solid tumors.

IPSCIO Record ID: 237232

License Grant
With this amendment, in the event Licensor of the United Kingdom notifies Licensee that a Product License can be granted to Licensee with respect to Products against a Nominated Target, then upon receipt by Licensor of the applicable Acceptance Fee, Licensor agrees to grant and hereby grants to Licensee and its Affiliates a non-exclusive, royalty-bearing license, with the right to sublicense, under the Antibody Phage Display Patents and Licensor Know-How to Exploit Products against such Nominated Target in the Territory.
License Property
The Antibody Phage Display Patents include Single Domain Ligands, Receptors Comprising said Ligands, Methods for their Production and Use of Said Ligands and Receptors, and, Co-expression of Heteromeric Receptors, and, Method for Isolating Receptors Having a Preselected Specificity, and, A new method for tapping the immunological repertoire, and, Methods for producing members of specific binding pairs, and, Treatment of Cell Populations, and, Production of chimeric antibodies – a combinational approach, and, Production of anti-self antibodies from antibody segment repertoires and displayed on phage, and, Methods for producing members of specific binding pairs, and, SBP members with a chemical moiety covalently bound within the binding site; production and selection thereof, and, Recombinant Binding Proteins and peptides,and, Labelling and selection of Specified Binding Molecules.

The Licensor Know-how includes Licensor Training Manual Antibody Phage Display 2002, and, Licensor mammalian expression IgG vectors
pEUl.2 (human gamma-I heavy chain)
pEU3.2 (human kappa light chain)
pEU4.2 (human lambda light chain)
pEU8.2 (human gamma-4 heavy chain)

Field of Use
The agreement is for nominated target(s) which is(are) potentially useful for the development of any Diagnostic Antibody Product and/or any Therapeutic Antibody Product.

Diagnostic Antibody Product means any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction or disease management of a disorder for any indication outside the Excluded Field which contains, comprises or the process of development or manufacture of which utilizes a Licensor Licensable Antibody.  The term Diagnostic Antibody Product shall not include any Research Product.

Therapeutic Antibody Product means any preparation for the treatment or prevention of disease, infection or other condition in humans for any indication outside the Excluded Field which contains, comprises, or the process of development or manufacture of which utilizes, a Licensor Licensable Antibody. The term Therapeutic Antibody Product shall not include any Research Product.

Excluded Field means the discovery, isolation, characterization, research, development, and/or commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific rationale or activity is neuronal and/or glial mechanisms of action or neuroprotection
(a) neurodegenerative conditions, including but not limited to (i) Alzheimers disease, and (ii) Parkinsons disease, but in both instances, excluding the  treatment and/or prevention of neurodegenerative conditions in humans associated with P-amyloid deposition (including, without limitation, Alzheimers disease and/or Mild Cognitive Impairment, using either (A) immunological approaches directed at one or more epitopes of AP or any naturally occurring variants thereof, including, without limitation, the administration of an Antibody, or (B) use of a beta secretase inhibitor, including, without limitation, the administration of an Antibody);
(b) diabetic neuropathy;
(c) pain, including, but not limited to, (i) post-operative pain, (ii) chronic pain and (iii) neuropathic pain,
(d) spinal cord injury;
(e) multiple sclerosis; and/or
(f) stroke, as a disease of the cerebrovasculature.

The term Excluded Field shall not include the diagnosis, treatment and/or prevention of the above disease conditions caused by infectious pathogenic micro-organisms.

IPSCIO Record ID: 114137

License Grant
Licensee transferred certain products to the Scottish Licensor to apply it's technology and know-how to perform Delmmunisation.
License Property
Products shall mean and include Monoclonal Antibodies and IFN Products.

Monoclonal Antibodies shall mean and include collectively certain monoclonal antibodies specific for certain antigens and the cell lines which produce them (and which Licensee has the right to develop and commercialize) such Monoclonal Antibodies being  described more specifically in the Materials Transfer Agreement between the parties dated March 17, 1999, or otherwise specified as provided by Licensee pursuant to this Agreement.

IFN Products shall mean and include interferon and/or fusion proteins with interferon conjugated to an immunoglobulin Fc, preferably through a peptide linker, and the expression system therefor, as generally described in U.S. Patent No. 5,723,125 (IFN product), assigned to Licensee.

PRODUCTS
                                                        ISOTYPE OF STARTING
DESIGNATED NAME                     ANTIGEN                      ANTIBODY
—————                                         ——-                         ——————-
(1) 5D12                                            CD40                         Human IgG4

(2) 5A8                                               CD4                           Human IgG4

(3) 166-93                                          G-CSF Receptor      Murine IgG1
  
(4) 166-32 or                                      Factor D                   Human IgG1
                                                             IFNa-Fc                    Human IgG4

Delmmunised is the procedure using the technology, materials and know-how for the genetic engineering which removes potentially immunogenic sequences in the variable region of antibodies and introduces human constant regions to produce an antibody for therapeutic or In Vivo diagnostic purposes designed to avoid or substantially minimize immunogenic response In Vivo.

The technology is described in International Patent Application PCT/GB98/01473

Field of Use
This agreement pertains to the medical industry relating to antibodies for therapeutic or In Vivo diagnostic purposes.

IPSCIO Record ID: 243458

License Grant
Licensor grants, in the Field and within the Territory
– an exclusive right and license, with the right to sublicense, under Licensor’s interests in any Program Patent Rights and Program Technology relating to a Program Antibody, to make, have made, use, sell and import such Program Antibody;

– an exclusive right and license, without the right to sublicense, under Licensor’s interests in any Program Patent Rights directed to one or more Antibodies binding to and reactive with the same Target as a Program Antibody, including compositions containing, methods of using and methods of making such Antibodies, to make, have made, use, sell and import such related Antibodies.

– Licensee may sublicense the rights granted in this clause but only in conjunction with a sublicense under rights to a Program Antibody.

– a non-exclusive right and license, with the right to sublicense, under the Licensor Background Technology to make, have made, use, sell and import Program Antibodies;

– a non-exclusive right and license, with the right to sublicense, under any Patent Rights and Know-How Controlled by Licensor Covering any control antibodies provided by Licensor for the sole purpose of using such control antibodies to evaluate the Program Antibodies; and

– an exclusive right and license, with the right to sublicense, under any Program Patent Rights or other Patent Rights and Know-How Controlled by Licensor Covering each antibody-producing cell line created by Licensor that expresses a Program Antibody provided by Licensor, for the sole purpose of using such cell line to produce the applicable Program Antibody.

License Property
Licensee has designated VEGF-A the initial Target, and Licensor has accepted such Target into the Collaboration.

VEGF-A means the 165 amino acid polypeptide known as Vascular Endothelia Growth Factor-A, or any variant form thereof.

Field of Use
The antibodies are for use in the prevention or treatment of human diseases and conditions.  Field means the diagnosis, prevention, control and treatment of any human disease or condition excluding, until the expiration of the Chiron Exclusivity Period, Cancer. Upon expiration of the Chiron Exclusivity Period, Cancer shall immediately be included within the Field.

IPSCIO Record ID: 357950

License Grant
Licensor grants to Licensee, an affiliate, an exclusive, worldwide right and license, with the right to sublicense, under the Licensed Patents to research, Develop, manufacture, have manufactured, use, import and Commercialize and have Commercialized the Licensed Products, in and for the Field and to practice and have practiced any Licensed Processes, in and for the Field.

Effective immediately at the time Licensee is no longer deemed to be an Affiliate of Licensor, Licensor grants Licensee a non-exclusive license under Licensed rights in and to the Licensed Materials solely in support of the exercise of Licensees license rights.  Licensee shall not have the right and shall be prohibited from selling, transferring, or distributing the Licensed Materials to end users, except in the case where such end users are Licensor Affiliates or Sub licensees under this Agreement.

License Property
Licensor has rights to the Licensed Patents and Materials as granted by Dana Farber Cancer Institute.

Antibody means any antibody, any gene expressing such an antibody, any hybridoma producing such antibody, or any fragment, variant, derivative or construct thereof, or antibody fusion protein produced therefrom, including PEDgylated or multimeric versions thereof, whether polyclonal, monoclonal, multi-specific antibodies, e.g., bi-specific antibodies, human, humanized, chimeric, murine, synthetic, or from any other source, including without limitation, the full immunoglobin molecules (e.g. the IgG, IgM,IgE, IgA, and IgD molecules), and the antigen binding portions including Fab, Fab, F(ab)2, Fv, dAb, and CDR fragments, chimeric antibodies, diabodies, polypeptides, linear antibodies and single-chain antibodies (scFv) that contain any portion of an immunoglobulin that is sufficient to confer specific binding to an antigen.

The agreement is to develop and commercialize Licensor's fully human anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies.

Field of Use
The Field means all prophylactic, palliative, therapeutic or diagnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemias, Lymphomas, Multiple Myeloma and Waldentroms Macroglobulemia, but specifically excluding use in chimeric antigen receptor technology. Additionally, upon exercise of the Autoimmune Option, the Field shall include the prevention, diagnosis and treatment of Autoimmune Diseases.

Autoimmune Diseases means any disease which results from a loss of immune tolerance to self-antigens, including without limitation multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, sjogren syndrome, celiac disease, Graves disease, myasthenia gravis, Type I diabetes, idiopathic thrombocytopenic purpura, pemphigus vulgaris, among others, including any presentation or manifestation thereof.

IPSCIO Record ID: 260370

License Grant
The Regents grants to the Licensee a license under its rights in and to Patent Rights to make, have made, use, Sell, offer for Sale and import Licensed Products and to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

License Property
The Certain inventions are generally characterized as
—  High Affinity Human Antibodies to Novel Tumor Antigens;
—  Bi-specific Single Chain Fv scFv Antibody Molecule; and,
—  Human Erb-B Antibodies.
Field of Use
The Field of Use means use as a therapeutic or diagnostic in humans. The Field of Use specifically excludes providing Licensed Services to third parties; the Sale, transfer, lease, exchange or other disposition or provision of Biological Materials, other than as incorporated in Licensed Products for Sale or as expressly permitted in this Agreement; the making, using or Selling of Biological Materials or Licensed Products for use in drug discovery or as a research reagent (other than for the development of Licensed Products);  the making, using or Selling of Non-Patent Products; and (v) all other uses and applications of Biological Material or Licensed Products, except as expressly permitted in this Agreement.

IPSCIO Record ID: 296181

License Grant
The Parties have a collaboration and exclusive license agreement.  Under the terms of the amended agreement, Licensor granted an exclusive, sub-licensable worldwide license to research, develop, manufacture, market and sell products based on our proprietary technology.
The November amendment adds an additional dual-reactive antibody product candidate.
License Property
Licensor granted exclusive rights to three monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033) and PD-1 (TSR-042) and a bispecific antibody product candidates targeting PD-1 and LAG-3.

The AnaptysBio platform offers unmatched capabilities in antibody discovery, generation and optimization, and we are excited about the potential for these programs. We look forward to working with the AnaptysBio team to develop novel immuno-oncology-based approaches to a variety of tumors.

Field of Use
The field of use is for the discovery, generation and optimization of certain specified immunotherapy antibodies.  With the amendment, the field is for performing initial discovery and development of therapeutic antibodies with the goal of generating immunotherapy antibodies for use in the treatment of cancer.

IPSCIO Record ID: 222549

License Grant
For the research license, Licensor grants a non-exclusive, non-transferable license, under the Licensor Technology to immunize the Mice to make Antibodies against such Antigen, and to further evaluate the Antibodies generated during the Evaluation Period.

For the commercial license,  Licensor grant the following licenses, on an Licensee Target-by-Licensee Target basis
– a worldwide, exclusive, non-transferable license, with the right to grant a sublicense to its Affiliates, under the Licensor Technology to immunize the Mice to make Antibodies against such Licensee Target, and
– a worldwide exclusive license under the Licensor Technology, with the right to sublicense, to make, have made, import, have imported, use, offer for sale and sell Products containing Antibodies against such Licensor Target.

Licensee shall have no right to grant sublicenses to use the Mice, but may grant sublicenses under
the Licensee Technology to the extent necessary to develop, make, have made, import, use, offer for
sale and sell Products.

License Property
Licensor is the sole and exclusive owner of certain transgenic_ Mice (as defined below) useful for the preparation of fully human monoclonal antibodies;

Licensor Technology includes the Confidential Information and Mice, and patent rights which claims an invention which is necessary for the use of the Mice to prepare the Antibodies or to develop, produce, make, have made, import, have imported, use, offer for sale and sell the Antibodies.

The Product shall mean any composition or formulation comprising one or more Antibodies, or a portion thereof, for the diagnosis, prophylaxis or treatment of human disease.

Licensee Target shall mean an Antigen selected by Licensee for immunization of Licensors HuMAb mice to generate human antibodies directed against an Antigen, in each case, which Licensor has informed Licensee is available for licensing.

HuMAb -Mouse technology is a transgenic mouse system that creates high affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.

Field of Use
Licensee desires to use the Mice to evaluate their utility for the development of fully human monoclonal antibodies against specific antigens.

Incorporating this technology into Licensee's broad drug discovery program will significantly enhance Licensee continuing efforts to identify new drug candidates.

IPSCIO Record ID: 227238

License Grant
Research License; Supply of Mice; Materials ownership
Licensor hereby grants to Licensee, a Japanese corporation, and the Majority-Owned Affiliates of Licensee, solely as needed to exercise the rights that may be granted, a paid-up, non-exclusive license and/or sublicense of its rights, as the case may be, under the Licensed Technology, without the right to grant further sublicenses, to (i) Breed the XenoMouse Animals included solely for use in the Research Field in connection with activities described in subsections (ii) and (iii) of this Section 2.1.1, (ii) immunize such XenoMouse Animals solely with those Antigens that are Permitted Antigens at the time of immunization and (iii) use the Research Program Materials and Information solely for conducting research and development work within the scope of the Research Field.

Licensor hereby grants to Licensee, and the Majority-Owned Affiliates of Licensee solely as needed to practice the rights that may be granted in accordance with this agreement, a paid-up, non-exclusive license and/or sublicense, as the case may be, of its rights in the Licensor Materials and Information and all intellectual property rights Controlled by Licensor related thereto that are not licensed to Licensee pursuant to the license in subsection (a) above, solely to the extent that the Licensor Materials and Information are necessary or useful to Licensees practice of the license granted in subsection (a) above.

Option to enter into Product License Agreement
Licensor hereby grants to Japanese Licensee an exclusive option (an 'Option') to enter into a Product License Agreement with respect to those Permitted Antigens which have been designated as Product Antigens, as further described. Each calendar year during the term of this Agreement, Licensee may obtain up to Two (2) such Options with respect to Product Antigens, pursuant to the procedures set forth.

License Property
Licensed Technology shall mean the rights Controlled by Licensor in the Licensor Patent Rights and Licensor Know-How; provided, however, that the foregoing shall exclude the Excluded Technology.

Product shall mean (i) with regard to the Option Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to a Product Antigen or (b) Genetic Material encoding such an Antibody, wherein in respect of each Product, said Genetic Material does not encode multiple Antibodies; and (ii) with regard to a Product License Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to the Product Antigen (as defined in such Product License Agreement) or (b) Genetic Material encoding such an Antibody wherein, in respect of each Product, said Genetic Material does not encode multiple Antibodies.

Product Antigen shall mean (i) with regard to the Option Agreement, a Permitted Antigen as to which Licensee has obtained an Option, as further described in the Option Agreement; and (ii) with regard to a Product License Agreement, the Antigen described in the Product License Agreement.

Xenomouse Animals shall mean transgenic mice which are Controlled by Licensor and which contain unrearranged human immunoglobulin genes that are capable of producing human antibodies when immunized with an antigen.

XenoMouseâ„¢ is a leading technology for generating fully human antibody drugs useful in treating a wide range of diseases.

Field of Use
Field shall mean the use of Products (i) for human therapeutic, prophylactic and diagnostic medical purposes and as laboratory research reagen.

XenoMouseâ„¢ is a technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.

Research Field shall mean the immunization of XenoMouse Animals with Permitted Antigens, the use of materials derived or generated in whole or in part from such XenoMouse Animals that are so immunized, and the use of the XenoMouse Animals themselves, solely for the creation, identification, analysis, manufacture, research, and preclinical development of Products in the Field. For purposes of clarification, it is understood that 'immunization' of XenoMouse Animals with a Permitted Antigen includes the immunization of XenoMouse Animals with any formulation or construction of a Permitted Antigen, regardless of the three dimensional configuration of such Permitted Antigen, including, but not limited to, cell lines expressing such Permitted Antigen on their cell surface and chimeric molecules containing such Permitted Antigen; provided, however, that any research, development or use of Antibodies that bind to an excluded Antigen (other than to determine whether they bind to a Permitted Antigen) shall be outside of the scope of the licenses granted under the Option Agreement.

IPSCIO Record ID: 257239

License Grant
Licensor grants the German Licensee a non-exclusive, worldwide license, under the Licensor Licensed Patents to Exploit Licensed Products other than BiTE Products and BiTE Research Products.

Licensor grants an exclusive, worldwide, perpetual, irrevocable, non-terminable, license, with the right to grant and authorize the grant of sublicenses, under the Licensor Licensed Patents to Exploit any BiTE Products and BiTE Research Products.

License Property
Licensed Product means any SCA Product, Non-Human SCA Product, Research Product, Industrial SCA Product, BiTE Product, or BiTE Research Product, the composition, manufacture, use of which is claimed by one or more Valid Claims of the Consolidated Patent Portfolio.

This additional amendment added patent 5,223,409, entitled Directed evolution of novel binding proteins.

BiTE Product means any composition or formulation consisting of, containing or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells for the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions, but excluding any BiTE Research Product.

Diagnostic SCA (Single Chain Antibodies) Product means an SCA Product that is under development, approved or used for the diagnosis of human diseases or conditions.

Licensee Pipeline Product means any Licensed Product, other than a BiTE Product or BiTE Research Product, as to which Licensee obtains or retains Commercialization Rights, whether exclusive or co-exclusive, in one or more Major Market Countries, or Licensee or any of its Affiliates has filed or will file an IND in its own name.

Industrial SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies intended for any use other than for research or the diagnosis, prophylaxis, or treatment of disease or conditions in humans and other animals.

Licensor Pipeline Product means any Licensed Product as to which Licensor obtains or retains Commercialization Rights, whether exclusive or co-exclusive, in one or more Major Market Countries, or Licensor or its Affiliates has filed or will file an IND in its own name.

Non-Human SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies under development, approved or used for the diagnosis, prophylaxis or treatment of non-human diseases or conditions, but excluding any BiTE Products.

Research Product means a product consisting of, containing or comprising one or more Single Chain Antibodies used for research purposes and not intended, under development or used for the diagnosis, prophylaxis or treatment of human or non-human diseases or conditions, but excluding any BiTE Research Product.

SCA Product means any composition or formulation consisting of, containing or comprising one or more Single Chain Antibodies that is under development, approved or used for the diagnosis, prophylaxis or treatment of human diseases or conditions, but excluding any BiTE Product.

Field of Use
The field of use is Products for Radioimmunoguided Surgery™ (RIGS®), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody, and,

Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and,

Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis Factor alpha (TNF-a) or Lymphotoxin, and, Single Chain Antibodies that bind to OP-1 or related proteins.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 240615

License Grant
The Parties previously entered into an Amended and Restated Development and License Agreement governing the Parties’ joint development of anti-CD40 antibodies.

Licensor has discontinued the anti-CD40 antibody program thereunder, and Licensee now wishes to continue development of anti-CD40 antibodies on its own.

As of the effective date, the Prior Agreement is terminated in its entirety.

For the Grant under Licensor CD40 Know How,  Licensor grants a license under the Licensor CD40 Know How, to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

For the Grant under Licensor CD40 Patents, Licensor grants a license under the Licensor CD40 Patents, to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

For the Grant under Licensor Patents,  Licensor grants a license under the Licensor Patents, to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

For the Right to Use Materials and Technology,  Licensor grants a license under Licensors rights in the Materials and Technology, to use the Materials and Technology in the form supplied by Licensor to Licensee under this Agreement to research, develop, make or have made, use, import, export, sell or offer for sale, Licensed Products in the Field in the Territory.

License Property
Antibody means the humanized anti-CD40 monoclonal antibody designated by Licensor as PRO64553.

Anti-CD40 Antibody means any anti-CD40 antibody, including, without limitation, the Antibody, any variant, including, without limitation, humanized versions, or fragment, including, without limitation, single-chain versions, of any such anti-CD40 antibody, conjugates, including conjugates with radionuclides, toxins or other compounds, of any of the foregoing which, in each case, was developed by Licensor in its performance of the Prior Agreement.

Licensor CD40 Patents include, no. 60/280805 and no. 10/099,818 entitled Combination Therapy.

Licensed Product means any product containing an Anti-CD40 Antibody.

SGN-40 is a humanized monoclonal antibody that targets the CD40 antigen, which is highly expressed on most B lineage hematologic malignancies including non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. CD40 is also found on many types of solid tumors, including bladder, renal and ovarian cancer, and may play a role in immunologic diseases.

Field of Use
SGN-40 is a humanized monoclonal antibody currently in Phase I and Phase II clinical trials for multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.